Hypothesis

Age‑related decline of the colonic bacterium Clostridium sporogenes reduces production of indole‑3‑propionic acid (IPA), weakening aryl hydrocarbon receptor (AhR)–dependent serotonin synthesis in enterochromaffin cells. This diminishes vagal afferent tone, disinhibits microglial NLRP3 inflammasome activation, and accelerates cognitive decline.

Mechanistic Rationale

The gut‑brain axis influences aging through metabolites that act on host receptors. IPA, a tryptophan catabolite produced by C. sporogenes, is a potent AhR agonist that boosts tryptophan hydroxylase 1 (TPH1) activity in gut enterochromaffin cells, increasing serotonin release [1]. Serotonin released into the lamina propria activates vagal sensory neurons via 5‑HT3 receptors, conveying inhibitory signals to the nucleus tractus solitarius and subsequently to the dorsal vagal complex, which dampens sympathetic outflow and microglial priming [2]. Aging is associated with a loss of C. sporogenes abundance and lower fecal IPA levels [3]. Without sufficient IPA‑AhR signaling, serotonergic vagal tone falls, removing a brake on microglial NLRP3 inflammasome activation. Consequently, microglia release IL‑1β and IL‑18, driving neuroinflammation and synaptic loss in the hippocampus.

This links two strands from the seed work: (1) metabolite‑driven endothelial senescence (PAA) and (2) vagal disruption by medium‑chain fatty acids [2]. Here, the vagal pathway is modulated not by excitatory signals but by a loss of inhibitory serotonergic input, providing a testable node where microbial ecology directly

Hypothesis

Indole‑3‑propionic acid (IPA) activates the pregnane X receptor (PXR) in intestinal epithelial cells, which in turn attenuates mTORC1 activity to shift cellular resources from proliferation toward barrier‑strengthening programs.

Rationale

• IPA‑PXR signaling upregulates tight‑junction proteins (Occludin, Claudin‑1, Claudin‑4, ZO‑1) and suppresses NF‑κB/TLR4‑driven inflammation【1】.
• mTORC1 integrates nutrient status to control translation, growth, and proliferation; tissue‑specific mTOR modulation shows divergent effects on lifespan and function【2】.
• No study has directly connected PXR activation to mTORC1 regulation in the gut epithelium, despite both pathways governing barrier homeostasis.

We propose that ligand‑bound PXR recruits a corepressor complex that includes DEPTOR or TSC2, leading to reduced Rheb‑GTP loading and diminished mTORC1 signaling. This creates a feedback loop where enhanced barrier integrity reduces microbial translocation, lowering luminal stimuli that would otherwise activate mTORC1 via growth‑factor pathways.

Testable Predictions

1. Pharmacological activation of PXR with IPA (or a selective agonist) in human colonic organoids will decrease phosphorylated S6K (p‑S6K) and 4E‑BP1 levels within 2 h, an effect abolished in PXR‑KO organoids.
2. Genetic loss of PXR in intestinal epithelium (Villin‑Cre;Pxr^fl/fl mice) will result in elevated baseline mTORC1 activity (higher p‑S6K) and increased crypt proliferation (Ki‑67^+ cells) despite unchanged nutrient intake.
3. Rescue experiment: treating PXR‑deficient mice with

Core hypothesis

Repeated or high‑dose administration of BPC‑157 and TB‑500 stimulates rapid fibroblast proliferation, angiogenesis and collagen deposition. These processes consume large amounts of NAD+ through PARP‑mediated DNA repair, heightened mitochondrial biosynthesis, and sirtuin‑dependent deacetylation of repair factors. If the NAD+ pool cannot be replenished faster than it is used, the cell experiences a transient NAD+ deficit that activates AMPK and inhibits mTORC1, leading to a compensatory downregulation of anabolic programs—essentially a metabolic 'budget cut' that mirrors the aging‑related NAD+ decline described in the seed idea. Thus, peptide‑induced repair may accelerate the very NAD+ loss it aims to counteract unless dosing schedules allow recovery periods.

Mechanistic rationale

• BPC‑157 activates VEGFR2 → Akt → eNOS → NO production, driving angiogenesis and VEGF‑stimulated endothelial mitosis. Endothelial S‑phase entry raises NAD+ consumption via PARP1 activity during DNA replication and repair [1]
• TB‑500 remodels actin cytoskeleton and upregulates VEGFA/angiopoietin‑2/Tie2, promoting fibroblast migration and collagen fibrillogenesis. Collagen synthesis requires proline hydroxylation and lysine oxidation, reactions that draw on NAD+‑dependent oxidases [2]
• Both peptides increase cellular proliferation, which elevates NADH shuttling to mitochondria for ATP generation, increasing the

Hypothesis

Senescent keratocytes accumulate with age and secrete a pro‑fibrotic secretome that up‑regulates lysyl oxidase (LOX) activity, leading to excessive collagen cross‑linking, stromal stiffening, and the observed decline in transparency. This positions cellular senescence, not simple keratocyte loss, as the primary driver of age‑related stromal pathology.

Mechanistic Rationale

• Keratocyte density declines linearly (~0.45%/yr) but histological studies show a disproportionate increase in p16^INK4a^‑positive cells in the anterior stroma after age 50, suggesting senescence expands relative to total cell loss.
• Senescent fibroblasts in other tissues secrete SASP factors (IL‑6, TGF‑β1, PDGF‑AA) that stimulate LOX transcription and secretion; LOX catalyzes lysine‑derived cross‑links that increase tensile strength and light scattering.
• The corneal stroma’s unique reliance on a highly ordered, low‑cross‑linked collagen lattice makes it especially vulnerable to even modest LOX up‑regulation, explaining the steep rise in stiffness from 67.9 kPa to >240 kPa with age.

Testable Predictions

1. Biomarker correlation – In human donor corneas stratified by age, the proportion of senescent keratocytes (p16^INK4a^ or SA‑β‑gal^+) will positively correlate with LOX activity (hydroxylysyl‑pyridinoline cross‑link levels) and stromal stiffness measured by Brillouin microscopy.
2. Causal link – Ex vivo culture of young corneal stroma treated with conditioned medium from senescent keratocytes will show increased LOX expression, elevated cross‑linking, and heightene

Background

Multi‑omics integration has revealed metabolic subtypes linked to prognosis and therapy response in cancers such as gastric carcinoma [2]. Proteomic and metabolomic layers expose functional states invisible to genomics, while AI‑driven fusion models achieve AUCs of 0.81–0.87 for early detection and therapy prediction [4]. Spatial technologies now co‑register transcriptomics, proteomics, and metabolomics within tumor microenvironments of glioma and colorectal cancer [5][6]. Despite these advances, a mechanistic link between dynamic metabolic rewiring and reversible epigenetic modifications that underlie therapy resistance remains poorly understood [7].

Hypothesis

We hypothesize that in EGFR‑mutant lung adenocarcinoma, increased glutamine uptake fuels de novo nucleotide biosynthesis, elevating intracellular acetyl‑CoA pools that drive histone H3 lysine 27 acetylation (H3K27ac) at enhancers of drug‑tolerant persister (DTP) programs. This epigenetic state is reversible upon glutamine withdrawal or glutaminase inhibition, sensitizing cells to EGFR tyrosine‑kinase inhibitors (TKIs).

Testable Predictions

1. EGFR‑TKI‑treated lung adenocarcinoma cells that survive treatment will show a significant increase in glutamine‑derived carbons incorporated into nucleotides, measurable by ^13C‑glutamine tracing and LC‑MS metabolomics [3].
2. The same surviving cells will display heightened H3K27ac at enhancer regions of DTP‑associated genes (e.g., AXL, IGF1R) detectable by spatial CUT&Tag coupled to imaging mass cytometry [5][6].
3. Pharmacologic inhibition of glutaminas

Background

Aged somatic cells frequently exhibit centrosome amplification yet avoid p53‑mediated arrest, suggesting a tolerance mechanism that permits survival with extra centrosomes.Chronic centrosome amplification through elevated PLK4 does not initiate tumorigenesis in mice with intact p53 Tumor‑suppressor p53 eliminates cells with severe centrosome defects, but chronic low‑level amplification persists in aging tissues.Cellular aging is associated with both centrosome aberrations and increased chromosomal instability Cells cope by clustering supernumerary centrosomes into a bipolar spindle, a process that nonetheless generates merotelic attachments and chromosome mis‑segregation.Cells with supernumerary centrosomes avoid lethal multipolar divisions by clustering them into a bipolar arrangement, but this adaptation promotes chromosome mis‑segregation through merotelic kinetochore attachments during transient multipolar states Extra centrosomes exert unequal pulling forces on chromosomes, leading to aneuploidy even when cells divide bipolar The E3 ubiquitin ligase TRIM37 restrains centrosome over‑duplication by degrading Centrobin and blocking PLK4 condensates,[TRIM37 controls stability of centrosomal proteins like Centrobin and preve

Hypothesis

Elevating NAD+ levels in hematopoietic stem cells (HSCs) rejuvenates immune surveillance by reducing mitochondrial DNA release and cGAS‑STING activation, thereby breaking the inflammaging feedback loop that drives systemic aging.

Mechanistic Rationale

• NAD+ decline with age impairs sirtuin activity, leading to hyperacetylated mitochondrial proteins and increased mitochondrial ROS, which promotes mtDNA efflux into the cytosol 1.
• Cytosolic mtDNA activates the cGAS‑STING pathway in immune cells, driving NF‑κB–dependent SASP production and reinforcing senescence 2.
• Restoring NAD+ via precursors (e.g., NR or NMN) reactivates SIRT3/SIRT5, enhancing mitochondrial fidelity and limiting mtDNA leakage 3.
• Lower mtDNA release diminishes cGAS‑STING signaling, reducing SASP from senescent T cells, macrophages, and neutrophils, and curbing the feed‑forward loop that spreads senescence to parenchyma 4.
• Consequently, a youthful HSC compartment generates a balanced lymphoid‑myeloid output, improving clearance of senescent cells and decreasing tissue‑level inflammation 5.

Testable Predictions

1. In aged mice, NAD+ supplementation will decrease cytosolic mtDNA in HSCs and downstream immune cells, measurable by reduced cGAMP levels and STING phosphorylation.
2. This biochemical shift will cor

Hypothesis

Aging is not a passive byproduct but an actively regulated program mediated by a conserved senescence signaling hub (SSH) that translates reproductive and metabolic cues into somatic decline. The SSH enforces a trade‑off: high activity favors early‑life reproduction by diverting resources from maintenance, while low activity extends lifespan at the cost of reduced fecundity. This mechanism satisfies the conditions of antagonistic pleiotropy without invoking group selection, because the hub’s output is tuned individually based on local energetic state.

Mechanistic Basis

• The SSH centers on the insulin/IGF‑1‑like signaling (IIS) node, FOXO transcription factors, and the mTOR complex, which together regulate a set of senescence‑effector genes (e.g., p16^INK4a, SASP components) across species [3].
• Reproductive tissue secretes gonad‑derived peptides (e.g., Drosophila DILPs, mammalian gonadotropin‑releasing hormone) that potentiate IIS activity, thereby linking gonad status to somatic aging [4].
• Energy‑sensing pathways (AMPK, SIRT1) antagonize the SSH by promoting FOXO nuclear retention and inhibiting mTOR, providing a reversible switch that can be modulated by nutrient availability or pharmacologic agents [2].
• In negligibly senescent species, the SSH exhibits attenuated sensitivity to gonad‑derived signals, allowing constitutive FOXO activity and sustained maintenance [[1](https://pmc.ncbi.nlm

Hypothesis

In aging cells, declining NAD+ reduces SIRT1 activity, leading to hyperacetylation of the selective autophagy receptor p62/SQSTM1. Hyperacetylated p62 exhibits lower affinity for ubiquitin chains on damaged mitochondria but higher affinity for ubiquitin signals on the endoplasmic reticulum. This altered binding preference re‑ranks the autophagy cargo hierarchy: ER‑phagy is favored over mitophagy despite mitochondrial damage being the more lethal stress. Restoring NAD+‑dependent SIRT1 activity (or mimicking p62 deacetylation) should reinstate the original hierarchy—prioritizing mitochondrial clearance—and thereby lower lactate production by reducing reliance on glycolysis.

Mechanistic Reasoning

1. Sirtuin‑dependent acetylation switch – SIRT1 directly deacetylates lysine residues on p62 (e.g., K420) that lie within its ubiquitin‑associated (UBA) domain. Deacetylation increases the electrostatic complementarity between the UBA domain and poly‑ubiquitin chains, boosting mitochondrial cargo capture. When NAD+ falls, SIRT1 activity drops, p62 remains acetylated, and its UBA domain binds ubiquitin more weakly, shifting preference toward ubiquitin‑rich ER‑phagy substrates that rely on distinct adaptor motifs (e.g., FAM134B‑LC3 interacting region).

2. Competition for limiting LC3 pools – Autophagosome formation is constrained by available LC3/GABARAP. Acetylated p62, with reduced ubiquitin affinity, spends more time in a "search" state, effectively increasing its apparent concentration and out‑competing other receptors (OPTN, NDP52) for LC3 bindin

AKG supplementation drives TET‑mediated demethylation that preferentially targets the inactive X chromosome, reactivating a subset of escape genes and re‑establishing balanced maternal/paternal expression. This reactivation improves cellular resilience to oxidative and proteostatic stress, thereby extending lifespan more markedly in females who retain two X chromosomes. The hypothesis is testable by measuring allele‑specific expression and methylation status of X‑linked escape loci in tissues from male and female mice treated with AKG versus control, predicting a greater increase in biallelic expression and reduced promoter methylation on the silent X in females. If AKG’s lifespan effect depends on this X‑chromosome‑specific epigenetic remodeling, then genetic attenuation of TET activity or forced skewing of X‑inactivation should abolish the female‑biased longevity benefit without affecting male response.

Recent work shows that XX mice outlive XY mice irrespective of gonadal sex, pointing to X‑chromosome dosage as a hormonal‑independent longevity factor[1]. Approximately 15‑25 % of X‑linked genes escape inactivation, enriching pathways for stress response and metabolism[2]. AKG is an essential cofactor for TET enzymes that oxidize 5‑methylcytosine, initiating DNA demethylation[3]. In humans, AKG supplementation lowers biological age by about eight years as measured by methylation clocks[4], and lifespan extension is more pronounced in female mice than males[5]. Centenarians display less skewed X‑inactivation, preserving a ~50:50 maternal:paternal ratio that correlates wit

We hypothesize that an individual's baseline gut microbiome redox phenotype determines whether berberine exerts its glucose‑lowering action primarily through AMPK activation or through mitochondrial complex I inhibition, thereby explaining the large inter‑individual variability observed in clinical trials and self‑tracking data.

Mechanistic Rationale

Berberine can activate AMPK in liver, muscle and fat, increasing GLUT4‑mediated glucose uptake and suppressing hepatic gluconeogenesis 3. In parallel, berberine inhibits mitochondrial complex I, lowering ATP production and shifting cellular metabolism toward glycolysis, a mechanism shared with metformin 4. The relative contribution of each pathway may depend on the intracellular NAD⁺/NADH ratio, which is heavily influenced by microbial metabolites such as short‑chain fatty acids (SCFAs) and bile acids that modulate host redox state 2. Individuals whose gut microbiota produce high levels of butyrate and secondary bile acids tend to maintain a more oxidized hepatic NAD⁺ pool, favoring AMPK activation; conversely, a microbiota enriched in lactate‑producing or hydrogen‑generating species creates a more reduced environment, potentiating complex I inhibition.

Testable Predictions

1. Stratified biomarker signature – Participants with high fec

Social purpose enhances mitophagy flux, leading to better functional aging outcomes without necessarily altering epigenetic age. This hypothesis bridges the gap between mouse longevity interventions that fail to translate to human hard endpoints [1][2] and the observation that epigenetic clock revisions often decouple from survival benefits [4][5]. We propose that perceived meaning activates β‑adrenergic signaling, which raises intracellular cAMP, activates AMPK and PGC‑1α, and thereby stimulates the PINK1/Parkin mitophagy pathway. Improved mitochondrial quality preserves muscle strength, cardiovascular capacity, and cognitive performance—endpoints that matter more than methylation clocks.

To test this, we propose a 12‑month, two‑arm randomized trial in adults aged 60‑80. Arm A receives a structured purpose‑finding program (weekly volunteer coaching, mentorship, and reflective journaling). Arm B receives an active control of health education sessions matched for time and social contact. Primary outcomes are change in hand‑grip strength, VO₂max, and the Short Physical Performance Battery at month 12. Secondary outcomes include plasma markers of mitophagy (cell‑free mitochondrial DNA, LC3‑II/I ratio, p62 levels), inflammatory cytokines, and epigenetic age (GrimAge, PhenoAge) measured at baseline, 6, and 12 months. We will also monitor adherence, adverse events, and concomitant exercise.

If the purpose arm shows a significant increase in mitophagy biomarkers accompanied by improved strength and endurance, while epigenetic age remains unchanged relative to control, the hypoth

Hypothesis

Cyclic administration of OSK mRNA packaged in lipid nanoparticles functionalized with tissue‑specific ligands (galactose for hepatocytes, transferrin for neurons, and peptide‑based ligands for muscle) together with intermittent NAD+ precursor supplementation will achieve sustained epigenetic rejuvenation across liver, brain, and skeletal muscle without inducing tumorigenic transformation, outperforming AAV‑mediated OSK in terms of repeatability and safety.

Rationale

Partial reprogramming resets epigenetic age by transient OSK expression, yet delivery remains the bottleneck. AAV provides long‑term expression but poses immunogenicity and re‑dosing limits, while naked mRNA‑LNP offers vaccine‑like repeatability but suffers from poor tissue selectivity. Recent work shows that metabolic cofactors such as B12 enhance reprogramming efficiency [8]; NAD+ boosters similarly improve sirtuin activity and chromatin remodeling, lowering the OSK exposure needed for rejuvenation. Ligand‑decorated LNPs have demonstrated organ‑specific mRNA delivery in vaccine and therapeutic contexts, suggesting a feasible path to target reprogramming factors where they are most needed while sparing off‑target tissues.

Predictions

If the hypothesis is correct, aged mice receiving the proposed regimen will show:

• A significant reduction in epigenetic age (measured by Horvath‑style clocks) in liver, hippocampus, and gastrocnemius after four cycles, comparable to or exceeding the 109% lifespan extension seen with AAV‑OSK [1].
• Improved functional assays: hepatic glucose tolerance, neuron

The mitochondrial epigenome, not its sequence, sets the tempo of adipose tissue aging.

Hypothesis

Chronic hypoxia in obese adipose tissue increases METTL4‑mediated N6‑methyldeoxyadenosine (6mA) methylation of mtDNA. This epigenetic mark suppresses mitochondrial transcription and shifts metabolite export toward succinate. Elevated succinate stabilizes HIF1α and activates the NLRP3 inflammasome, creating a feed‑forward loop that couples mitochondrial epigenetic silencing to both collagen cross‑linking (fibrosis) and inflammasome‑driven inflammation. Conversely, demethylation of mtDNA 6mA by ALKBH1 restores oxidative phosphorylation, lowers succinate, and attenuates both fibrotic and inflammatory phenotypes.

Mechanistic Model

• Hypoxia → METTL4 ↑ → mtDNA 6mA ↑ (cite [2])
• mtDNA 6mA ↑ → TFAM binding ↓ → OXPHOS ↓ → succinate efflux ↑
• Succinate ↑ → inhibition of prolyl hydroxylases → HIF1α stabilization → lysyl oxidase ↑ → collagen cross‑linking ↑ (cite [4]; succinate‑HIF1α link [5])
• Succinate ↑ → ROS production → NLRP3 inflammasome activation → IL‑1β/IL‑18 release ↑ (cite [7])
• ALKBH1 ↑ → mtDNA 6mA ↓ → TFAM binding restored → OXPHOS ↑ → succinate ↓ → HIF1α/NLRP3 ↓ → fibrosis and inflammation attenuated

Testable Predictions

1. Adipocyte‑specific METTL4 knockdown under hypoxic conditions will reduce mtDNA 6mA, increase mtDNA copy number, lower extracellular succinate, decrease HIF1α protein and lysyl oxidase activity, and diminish collagen deposition.
2. Conversely, METTL4 overexpression will exacerbate 6mA accumulation, succinate release, HIF

Background

Endothelial dysfunction initiates vascular aging through eNOS uncoupling caused by BH4 oxidation, elevated ADMA, arginase II activity, and reduced Niban phosphorylation[1,2,3]. These disturbances increase superoxide production, diminish NO bioavailability, and promote arterial stiffness measured by PWV[4,5]. The bidirectional relationship between dysfunction and stiffness creates a vicious loop[6]. Despite mechanistic promise, BH4 supplementation shows inconsistent clinical benefit, suggesting unaddressed contributors[7].

Hypothesis

Mitochondrial-derived extracellular vesicles (mtEVs) released from aged endothelial and smooth‑muscle cells carry oxidized mitochondrial DNA (mtDNA) and activate endothelial TLR9. TLR9 signaling potentiates NADPH oxidase (NOX2/NOX4) activity, generating superoxide that further oxidizes BH4 and sustains eNOS uncoupling. This mtEV‑TLR9‑NOX axis operates parallel to classical ROS sources and explains why antioxidant‑focused interventions fail to fully restore NO bioavailability in subsets of older adults.

Mechanistic Rationale

1. mtEV release increases with vascular senescence – senescent cells shed EVs enriched in damaged mtDNA[[2](https://www.oaepublish.com/art

Hypothesis

The gut microbiota possesses an intrinsic biological age that advances independently of host chronological age and drives inflammaging through microbial‑derived phenylacetic acid and associated senescence‑associated secretory phenotypes. This microbial age predicts loss of cholinergic neurons in the enteric nervous system, gut barrier leak, and downstream neurocognitive decline earlier than host‑based biomarkers.

Mechanistic Basis

Aged microbiota exhibit a metagenomic signature of decreased diversity, enrichment of pathobionts, and altered metabolic output that raises circulating phenylacetic acid ([1]). Phenylacetic acid acts as a danger‑associated molecular pattern, stimulating TLR2/4 on enteric glia and macrophages, which release IL‑1β and TNF‑α. These cytokines impair cholinergic neuron survival by reducing NAD⁺ levels and increasing oxidative stress, reproducing the ENS degeneration seen in aging ([2]). Simultaneously, microbial SASP factors amplify intestinal permeability, allowing bacterial products to reach the systemic circulation and fuel microglial activation in the brain. Thus, microbiota aging initiates a feed‑forward loop that accelerates host inflammaging.

Testable Predictions

1. Individuals with an elevated gut‑microbiota age (measured by a metagenomic clock) will show higher plasma phenylacetic acid, greater ENS cholinergic neuron loss, and poorer performance on memory and motor tasks, independent of their host age.
2. A 48‑hour intermittent fasting protocol administered twice weekly for 12 weeks will reduce microbial age, lower phenyl

Hypothesis

With age, human osteoblasts show declining O‑glycosylation of osteocalcin at the position analogous to mouse Ser8, shortening its half‑life and shifting its signaling at the adrenal GPR158 receptor from Gαs‑driven cAMP production toward β‑arrestin‑biased pathways. This bias reduces glucocorticoid synthesis while weakening the exercise‑induced IL‑6/osteocalcin feed‑forward loop that supports muscle performance. The loss of stable, O‑glycosylated osteocalcin also triggers osteocytes to release more sclerostin, which acts as a proinflammatory cytokine that further suppresses adrenal steroidogenesis.

Mechanistic Basis

• O‑glycosylation loss: In mice, redundant GalNAc‑Ts (T1/2/3/6) add O‑GlcNAc to Ser8, prolonging osteocalcin half‑life independent of carboxylation[3]. Humans lack the equivalent site and rely on carboxylation for stability; aging lowers γ‑glutamyl carboxylase activity, decreasing the pool of undercarboxylated, active osteocalcin[2].
• Receptor bias: GPR158 can signal via Gαs (cAMP) or β‑arrestin scaffolds. Short‑lived, poorly modified osteocalcin favors β‑arrestin recruitment, which engages MAPK phosphatases that blunt STAR expression, cutting cortisol output[1].
• Muscle‑bone loop disruption: Exercise‑induced IL‑6 stimulates osteoclast resorption to release osteocalcin[5]. With less circulating osteocalcin, IL‑6 signaling falls, lowering muscle IGF‑1 and impairing performance[2].
• Sclerostin rise: Osteocytes sense low mechanical loading and low osteocalcin, upregulating sclerostin secretion. Secreted sclerostin binds LRP5/6 o

Hypothesis

We propose that the circadian clock suppresses LINE1 retrotransposon activity through a NAD+‑SIRT1 axis that is directly gated by feeding time. In this model, BMAL1‑CLOCK drives daily oscillations of NAD+ biosynthesis via NAMPT, producing peak NAD+ levels during the biological active phase. High NAD+ activates SIRT1, which deacetylates histone H3K9 at LINE1 promoters, reinforcing heterochromatin and blocking transcription. When food intake is shifted to the rest phase, NAD+ rhythms dampen, SIRT1 activity falls, LINE1 derepression rises, and genomic instability accelerates aging phenotypes.

Mechanistic Rationale

• BMAL1‑dependent NAD+ synthesis: BMAL1:CLOCK heterodimers transcriptionally activate NAMPT, the rate‑limiting enzyme in the NAD+ salvage pathway, creating a circadian NAD+ peak that aligns with the active period (1).
• SIRT1 recruitment to LINE1: SIRT1 deacetylates H3K9 and promotes HP1 binding, establishing a repressive chromatin state that has been shown to limit retrotransposon transcription in multiple cell types (5).
• Feeding‑time control of NAD+: Time‑restricted feeding that matches the active phase sustains NAD+ oscillations, whereas misaligned feeding flattens the NAD+ curve, reducing SIRT1 activity (6).
• Consequences of LINE1 activation: Increased LINE1 retrotransposition causes DNA damage, senescence‑associated secretory phenotype, and stem‑cell exhaustion, ha